Acadia Pharmaceuticals And Stoke Therapeutics Announce Collaboration To Pursue Multiple RNA-based Treatments For Severe And Rare Genetic Neurodevelopmental Diseases
– Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program
– Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett
Stoke Touts Early Signs Of Efficacy For Antisense Drug In Dravet Syndrome
Stoke Therapeutics Inc (NASDAQ: STOK)
B of A Securities Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $43
B of A Securities analyst Greg Harrison initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and announces Price Target of $43.
JP Morgan Upgrades Stoke Therapeutics to Overweight, Announces $41 Price Target
JP Morgan analyst Jessica Fye upgrades Stoke Therapeutics (NASDAQ:STOK) from Neutral to Overweight and announces $41 price target.
Stoke Therapeutics Highlights Presentation From Co.’s Dravet Syndrome Program At American Epilepsy Society Dec. 5, 1 p.m. EST
– Data from the positive interim analysis of the Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome will be presented –
BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics,
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)